View the official press release distributed through PR Newswire.
nRichDX Revolution Sample Prep System™ for cfDNA extraction and Agena's MassARRAY® platform for detection of rare liquid biopsy analytes.
SAN DIEGO and IRVINE, Calif., April 14, 2023 – Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researchers developing liquid biopsy applications on the Agena MassARRAY platform.
The early detection of rare oncology analytes is the primary goal of liquid biopsy research and development; however, existing methods of analyte extraction are not often able to extract sufficient rare analytes, like circulating cell-free tumor DNA (ctDNA), to enable the development of highly sensitive liquid biopsy-based assays.
Connecting Sample Preparation and Downstream Detection
Revolution sample preparation paired with Agena's MassARRAY® detection platform.
Expanded an existing technical collaboration into a commercial partnership
Co-promotion of solutions for researchers developing liquid biopsy applications
Revolution Sample Prep System™ for upstream analyte extraction
MassARRAY® platform for downstream detection of rare liquid biopsy analytes
Increasing the Molecular Input Available for Detection
The Revolution Sample Prep System routinely extracts higher yields of even the rarest of variant transcripts from bodily fluids as compared to other methods, which in turn increases the detection sensitivity of the MassARRAY platform.
Together, the companies described the systems as an advancement toward detection of rare cancer genetic targets in liquid biopsy samples, with applications in cancer detection, therapy selection, treatment monitoring, and minimal residual disease.
“Agena is pleased to collaborate with nRichDX to provide clinical investigators with research solutions that can deliver greater assay sensitivity and improved detection of rare analytes on the MassARRAY platform.”
“Liquid biopsy test developers are looking forward to the creation of highly sensitive assays that can use body fluids as inputs, especially in the area of early detection of cancer which requires extraction retrieval and detection of the rarest of alterations,” Irwin said.
“More sensitive detection of rare cancer markers translates to the earlier detection and treatment of cancer…the shared goal of liquid biopsy test developers and oncologists.”
“The combination of the Agena MassARRAY and Revolution Sample Prep System platforms represents a meaningful advancement for liquid biopsy development,” Curtis said.
Joint Research at AACR 2023
The companies planned to jointly present data at the American Association for Cancer Research (AACR) meeting, April 14-19, 2023 in Orlando, Florida.
The announcement also stated that the companies planned to continue their partnership by presenting additional data at future meetings and preparing additional resources for liquid biopsy researchers.
Explore Reference MaterialsUpstream Sample Preparation for Liquid Biopsy
The commercial collaboration combined nRichDX's Revolution Sample Prep System with Agena Bioscience's MassARRAY platform to support researchers investigating rare molecular targets in liquid biopsy samples.
Explore the Revolution PlatformAbout nRichDX
nRichDX® is an emerging leader in sample prep solutions for the isolation of cfDNA, ctDNA, RNA and other rare analytes. The patented Revolution Sample Prep System™ was engineered specifically for liquid biopsy applications.
It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform that can process from 1 mL to 20 mL of plasma or urine sample volumes and 1 mL to 40 mL of blood in a single extraction using the company's unique nRicher Cartridge™.
Unlike other methods, Revolution sample prep doesn't require yield-lowering sample pooling, bead recycling, or sample transfer steps. nRichDX helps solve one of precision medicine's greatest problems: inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte.
Learn more about nRichDXAbout Agena Bioscience
Agena Bioscience® offers the MassARRAY® System, an open platform that enables labs to provide a highly multiplexed result in a simple workflow.
At the time of the announcement, Agena Bioscience was headquartered in San Diego, California and marketed its products in more than 30 countries through direct sales offices in Germany, China and Australia and through an extensive network of distributors.
Agena Bioscience is a subsidiary of Mesa Labs, Inc.
Visit Agena Bioscience